A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)

The goal of this clinical trial is to see how well dostarlimab works when administered with the chemotherapy drugs carboplatin and paclitaxelin in treating EC in Chinese participants. The study aims to understand the treatments effectiveness, safety, how the drugs behave in the body, and whether it causes any immune reactions.

Trial Details

NCT ID
NCT07108270
Phase
PHASE2
Sponsor
GlaxoSmithKline
Status
RECRUITING
Cancer Type
Endometrial Cancer Uterine Cancer
Interventions
  • Dostarlimab
  • Carboplatin
  • Paclitaxel
Locations (sample)
  • Jinan, Shandong, China|36.66833,116.99722

Key Eligibility Criteria

  • Participant has histologically or cytologically proven EC with recurrent or advanced disease.
  • Participant has molecular subtype of defective mismatch repair (dMMR) or microsatellite instability high (MSI-H) determined by the central referenc…
  • Participant must have primary Stage III or Stage IV disease or first recurrent EC with a low potential for cure by radiation therapy or surgery alo…
  • Has primary Stage III to IV disease and is naive to systemic anticancer therapy for EC;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Endometrial Cancer Uterine Cancer Trials on Trialify →